Vivalytic
Receive your quote directly from the manufacturer.
The Vivalytic platform is a universal, fully automated all in one solution for molecular diagnostics. It is a cartridge-based platform enabling High-Plex and Low-Plex testing developed in partnership with Bosch. Vivalytic consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection. Randox multiplex Biochip Technology powers Vivalytic enabling multiple results from one patient sample.
Randox patented Biochip Technology allows simultaneous detection of multiple targets from a single patient sample. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction. Each biochip is prefabricated with spatially discrete testing regions (DTR’s), Each representing an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest. The High-Plex capabilities of Biochip Technology eliminates the need to run multiple time consuming and sample intensive assays.
The Vivalytic employs a unique testing menu covering a diverse range of respiratory, genitourinary and hospital acquired infections.
A case study from St Thomas’ Hospital in speeding up Candida auris detection and isolation
Craig Ryan, Molecular Product Manager at Randox Laboratories Ltd., hosts a discussion with Désirée Prossomariti, Guy’s and St Thomas’ NHS Foundation Trust, on the transformative impact of switching from culture-based testing to PCR for managing Candida auris. The conversation highlights the limitations of traditional methods, the outbreak that prompted change, and the successful implementation of Vivalytic cartridge-based PCR assays, which drastically reduced turnaround times from over 90 hours to just 26. This shift enabled faster patient isolation, reduced strain on biomedical scientists, and improved overall outbreak control. Prossomariti also shares operational insights and encourages other hospitals to consider PCR adoption for better patient management.
